Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years old who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were physician discretion.

Detailed Description
-----------------
Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were at physician discretion.

Official Title
-----------------
Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Clinical diagnosis of coronary heart disease Age >= 18 years old receiving any antiplatelet agents Informed written consent signed Exclusion Criteria: With severe disease and life expectancy for 6 months or less Difficult to attain follow-up situations judged by researchers (travel, speech or mental disorder, etc.) Taking part in an interventional clinical research

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Antiplatelet therapy<br>patients with coronary artery disease receiving any antiplatelet therapy, without any intervention by the investigators. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiac and cerebral events | a composite of all cause death, myocardial infarction, stroke or any revascularization or stroke | 12month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause death |  | 12month | 
| Stent thrombosis | by BARC definition | 12 month | 
| rehospitalization | any rehospitalization for cardiac or noncardiac reasons | 12 month | 
| any bleeding events | by BARC definition | 12 month | 
| recurrent angina |  | 12 month | 
| myocardial infarction |  | 12 months | 
| stroke |  | 12 months | 
| any revascularization |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary Artery Disease, antiplatelet therapy